Annals of Allergy, Asthma & Immunology 2018
This journal is to serve as an objective evidence-based forum for the allergy/immunology specialist to keep up to date on current clinical science (both research and practice-based) in the fields of allergy, asthma, and immunology. The emphasis of the journal will be to provide clinical and research information that is readily applicable to both the clinician and the researcher. Each issue of the Annals shall also provide opportunities to participate in accredited continuing medical education activities to enhance overall clinical proficiency.
• Clinical approach to the patient with refractory atopic dermatitis
• The atopic march: Critical evidence and clinical relevance
• What can we learn about predictors of atopy from birth cohorts and cord blood
• Phenotypes and endotypes of food allergy; A path to understanding the pathogenesis and prognosis
• Common questions in food allergy avoidance
• New treatment directions in food allergy
• Uses of biologics in allergic diseases: what to choose and when
• Occupational exposure and asthma
• Occupational dermatitis: How to identify the exposures, make the diagnosis, and treat the disease
• Where does health communication technology fit into allergy practice
• Hidden allergens in food allergy
• Management of food allergies and asthma in schools
• Who needs penicillin allergy testing?
• Unnecessary food allergy testing by primary care providers: ethical implications for the specialist
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American College of Allergy, Asthma & Immunology (ACAAI) designates this journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Allergist, immunologist and other allergy/immunology provider
Primary Care Providers
Overall Learning Objectives: Upon completion of this learning activity, participants should be able to:
• Discuss recent developments in the field of allergy, asthma and immunology
• Identify and evaluate various diagnostic and therapeutic strategies for treating patients
with symptoms related to Allergy, Asthma and Immunology
As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewers, and other individuals in a position to control or influence the content of an activity must disclose all relevant financial relationships with any commercial interest that have occurred within the past 12 months. All identified conflicts of interest must be resolved and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure be provided to the learners prior to the start of the activity. Individuals with no relevant financial relationships must also inform the learners that no relevant financial relationships exist. Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials. Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of ACAAI.
All identified conflicts of interest have been resolved.
Disclosure of Relevant Financial Relationships:
M. Stier has no relevant financial relationships to disclose. Any unapproved/investigative uses of therapeutic agents/devices discussed are appropriately noted. R.S.Peebles - he received research grants for NIH; J.A. Bernstein – PI, Consultant, Speaker for AstraZeneca, CSL Behring, Novartis/Genentech, and Shire, he received research grants and fees; Speaker for Baxalta, he received fees; Consultant for Imedics, he received fees; PI and Consultant for Boehringer Ingelheim and GlaxoSmithKline, he received research grants and fees. G. Krishnaswamy – Clinical Research for CSL Behring, he received a research grant; J. Oppenheimer – Consultant for DBV Technologies, GlaxoSmithKline, and Kaleo, he received other financial gains; Clinical research for AstraZeneca, Boehringer Ingelheim, and Novartis, he received research grants. M.H. Grayson – Clinical research for Polyphor, Ltd., he received a research grant. G.D. Marshall – Clinical Research for Stallergens and Sanofi, he received research grants.
Recognition of Commercial Support: This activity has not received external commercial support.
Copyright Statement: Copyright Ó 2017 American College of Allergy, Asthma & Immunology. All rights reserved.
CME Inquiries: Contact the American College of Allergy, Asthma & Immunology at firstname.lastname@example.org or 847-427-1200.